摘要 :
Background: The WHO dengue classification 1997 was revised in 2009 and the revised classification system has now been in use for the past decade. This study was carried out to compare the 1997 and revised classifications in assess...
展开
Background: The WHO dengue classification 1997 was revised in 2009 and the revised classification system has now been in use for the past decade. This study was carried out to compare the 1997 and revised classifications in assessing the severity of dengue infection among all age groups during a dengue outbreak in south-west India.
收起
摘要 :
Introduction: In 2009, the new World Health Organization (WHO) dengue case classification - dengue/severe dengue (D/SD) - was introduced, replacing the 1997 WHO dengue case classification: dengue fever/dengue haemorrhagic fever/de...
展开
Introduction: In 2009, the new World Health Organization (WHO) dengue case classification - dengue/severe dengue (D/SD) - was introduced, replacing the 1997 WHO dengue case classification: dengue fever/dengue haemorrhagic fever/dengue shock syndrome (DF/DHF/DSS).
收起
摘要 :
The novelties in WHO 5 th edition classification of genitourinary tumours are: a) nomenclature changes, including the replacement of the term “primitive neuroectodermal tumour” with “embryonic-type neuroectodermal tumour” and ...
展开
The novelties in WHO 5 th edition classification of genitourinary tumours are: a) nomenclature changes, including the replacement of the term “primitive neuroectodermal tumour” with “embryonic-type neuroectodermal tumour” and of “carcinoid” with “neuroendocrine tumour”. Also, seminoma is now placed in a “germinoma” family of tumours, while sertoliform cystoadenoma was moved from adnexal tumours to Sertoli cell tumours; b) new entities, specifically signet ring stromal tumour, myoid gonadal stromal tumour and well-differentiated papillary mesothelial tumour.
收起
摘要 :
This review focuses on the evolution and conceptual aspects of classifications for cutaneous lymphomas. The World Health Organization/European Organization for Research and Treatment of Cancer (WHO/EORTC) classification and the WH...
展开
This review focuses on the evolution and conceptual aspects of classifications for cutaneous lymphomas. The World Health Organization/European Organization for Research and Treatment of Cancer (WHO/EORTC) classification and the WHO classification (4th edn, 2008) represent the first widely accepted classifications for lymphomas, in which the complete spectrum of primary cutaneous lymphomas is included. These classifications for primary cutaneous lymphomas define disease entities with distinct clinical, histological, immunophenotypic and genetic features. Final diagnosis is based on a synoptic integration of these features and implies clinicopathological correlation as a pivotal element of the diagnostic approach for primary cutaneous lymphomas. The entities, their definitions and diagnostic criteria of cutaneous lymphomas listed in the WHO/EORTC and WHO classifications are presented. Recent changes in the terminology and staging, practical implications and future perspectives are discussed.
收起
摘要 :
Background: Gastric carcinoma is the third most common cause of cancer relatedmortality worldwide. The present study is taken up to provide an overview of thespectrum of malignancies, age and sex incidence and risk factor such as ...
展开
Background: Gastric carcinoma is the third most common cause of cancer relatedmortality worldwide. The present study is taken up to provide an overview of thespectrum of malignancies, age and sex incidence and risk factor such as tobacco usage,alcohol consumption, dietary intake and blood group analysis of gastricadenocarcinomas in South India.Martial and Methods: The present study is a two year retrospective study that includedall the cases received from 1st August, 2018 to 31st July 2020 in the department ofpathology, Guntur Medical College and Government General Hospital, Guntur.Results: A total of 49 cases were included in the study. The most common age group wassixth decade of life with male preponderance. Gastric outlet obstruction was the mostcommon presenting symptom. Tubular type of gastric adenocarcinoma was the mostcommon histopathological variant.Conclusion: Regardless of growing understanding of the risk factors, phenotypic andgenotypic alterations and diagnostic modalities, Gastric adenocarcinoma still linger tohave poor prognosis due to limited treatment options.
收起
摘要 :
It has been 12 yr since the publication of the last World Health Organization( WHO) classification of tumours of the prostate and bladder. During this time, significant new knowledge has been generated about the pathology and gene...
展开
It has been 12 yr since the publication of the last World Health Organization( WHO) classification of tumours of the prostate and bladder. During this time, significant new knowledge has been generated about the pathology and genetics of these tumours. Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 WHO classification. In most cases, it represents intraductal spread of aggressive prostatic carcinoma and should be separated from high-grade prostatic intraepithelial neoplasia. New acinar adenocarcinoma variants are microcystic adenocarcinoma and pleomorphic giant cell adenocarcinoma. Modifications to the Gleason grading system are incorporated into the 2016 WHO section on grading of prostate cancer, and it is recommended that the percentage of pattern 4 should be reported for Gleason score 7. The new WHO classification further recommends the recently developed prostate cancer grade grouping with five grade groups. For bladder cancer, the 2016 WHO classification continues to recommend the 1997 International Society of Urological Pathology grading classification. Newly described or better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential, which is frequently identified in patients with a prior history of urothelial carcinoma. Invasive urothelial carcinoma with divergent differentiation refers to tumours with some percentage of "usual type" urothelial carcinoma combined with other morphologies. Pathologists should mention the percentage of divergent histologies in the pathology report. Patient summary: Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 World Health Organization classification. Better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential. (C) 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
收起
摘要 :
In this study, we retrospectively compared the prognostic value of the 2016 WHO classification with the former classification in 387 patients with glioma treated at our institution. According to the new classification, diagnoses i...
展开
In this study, we retrospectively compared the prognostic value of the 2016 WHO classification with the former classification in 387 patients with glioma treated at our institution. According to the new classification, diagnoses included oligodendroglioma with isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion (5.4%), anaplastic oligodendroglioma with IDH mutation and 1p/19q co-deletion (3.4%), diffuse astrocytoma IDH-mutated (3.9%), anaplastic astrocytoma IDH-mutated (2.8%), glioblastoma IDH-mutated (7.8%), glioblastoma IDH-wildtype (58.4%), diffuse midline glioma H3 K27M mutation (2.6%), oligodendroglioma NOS (1.3%), anaplastic oligodendroglioma NOS (0.8%), diffuse astrocytoma IDH-wildtype (2.8%), and anaplastic astrocytoma IDH-wildtype (10.9%). The prognoses of IDH-mutated astrocytomas clearly varied according to tumor grade. However, we identified no survival difference between IDH-wildtype anaplastic astrocytomas and glioblastomas; additionally, these tumors showed similar gene expression profiles. After exclusion of those without 1p/19q co-deletion, patients with oligodendroglial tumors showed excellent survival regardless of tumor grade. Our evaluation of chromosomal aberrations suggests that the MAPK/PI3K pathway plays a role in acquired malignancy of astrocytic tumors, whereas TP53 participates in tumorigenesis. We suspect the RB pathway also plays a role in tumorigenesis of IDH-mutated gliomas. The new WHO classification more clearly reflects the tumorigenesis of gliomas and improves the prognostic power of classification.
收起
原文获取